An Observational Study Utilising Data from EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  ReMuS: Czech National Registry of Multiple Sclerosis, Czechia; Danish MS Registry
• Data sources (types):
  Disease registry

  Other
• Data sources (types), other:
  It is planned that data for this study will be sourced from EU national registries. The study will initially utilize data collected from European union national MS registry (ReMuS) and Danish MS Registry.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No